Benzinga - by Avi Kapoor, Benzinga Staff Writer.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. (NYSE:PFE)
- Dividend Yield: 5.96%
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and increased the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 70%.
- BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and raised the price target from $33 to $36 on May 2. This analyst has an accuracy rate of 68%.
- Recent News: Pfizer has reportedly settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.
- Dividend Yield: 5.46%
- Piper Sandler analyst DavidAmsellemmaintained an Overweight rating and raised the price target from $22 to $24 on April 29. This analyst has an accuracy rate of 66%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $27 to $22 on Oct. 11, 2023. This analyst has an accuracy rate of 70%.
- Recent News: Organon announced pricing of $1.0 billion senior notes offering.
- Dividend Yield: 5.36%
- BMO Capital analyst Evan Siegermanmaintained a Market Perform rating and cut the price target from $55 to $48 on April 26. This analyst has an accuracy rate of 60%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $51 to $52 on April 18. This analyst has an accuracy rate of 77%.
- Recent News: On April 25, Bristol Myers Squibb posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.